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ABSTRACT 
Background: Pulmonary rehabilitation (PR) is 
beneficial for patients with COPD, with improvement 
in exercise capacity and health-related quality of life. 
Despite these overall benefits, the responses to PR 
vary significantly among different individuals. It is not 
clear if PR is beneficial for patients with COPD and 
normal exercise capacity. Although it is believed that 
longer pulmonary rehabilitation programs can provide 
better results, most of the evidence comes from short-
term programs. 
Objective: The objective of this analysis was to 
determine the effectiveness of respiratory services 
provided in the hospital or community by respiratory 
therapists (RTs) in reducing health care utilization and 
improving patient outcomes. The aim was to evaluate 
the outcomes of a comprehensive pulmonary 
rehabilitation (PR) in chronic obstructive pulmonary 
disease. 
Methodology: All 65 Pakistani patients who met the 
inclusion criteria with ages between 40 to 65 years, 
including both male and female, with mild to severe 
COPD were enrolled in the study on the basis of 
convenient sampling. Informed consent was taken 
from each patient starting about the study and their 
rights to withdraw from study. A demographics detail 
(name, age, sex) was noted along with the necessary 
medical history. A questionnaire was made to see the 
effects of pulmonary rehabilitation in patients with 
COPD. All necessary tests were performed to evaluate 
the patient betterment completely. 
Results: The mean FEV1 in the subjects was 1.29 ± 
0.47 L/min, 64.8 ± 23.0% of predicted. Clinically 
there is a little effect on CXR pattern, FEV1 and 
FEV1/FVC after pulmonary rehabilitation. But overall 
quality of life improved after pulmonary rehabilitation. 
Mainly improvement occurs in peak expiratory flow 
rate, BORG dyspnea scale, 6 mint walk test distance 
(meters) and Oxygen saturation after rehabilitation. 
Conclusion: These results showed 
that patients with COPD had benefited from a 
comprehensive PR program in an out-patient setting 
regardless of disease severity. Exercise training can 
result in significant improvement in health-
related quality of life, exercise capacity, respiratory 
muscle strength, and exertional dyspnea in subjects 
with COPD and normal exercise capacity. 
Introduction 
Chronic obstructive pulmonary disease (COPD) is a 
preventable and treatable disease state characterized 
by airflow limitation that is not completely reversible. 
The airflow limitation is usually progressive and is 
associated with an abnormal inflammatory response of 
the lungs to noxious gaseous particles mainly caused 
by cigarette smoking. Although COPD affects the 
lungs and produces significant systemic consequences. 
(1) The most common symptoms of COPD are 
excessive sputum, SOB and a productive cough. (2) 
The  pursed lip breathing, barrel chest, paradoxical 
movement of chest (Hoovers sign) are also common. 
(3) 
Globally   tobacco smoking is primary and most 
important risk factor for COPD. (2)  In non-
smokers, passive smoke is responsible for about 20% 
of COPD cases. (3) The prevalence of COPD was 
modeled in 12 South-east Asian countries and 
estimated to be 6.3%, with highest prevalence in China 
(6.5%) and in Vietnam (6.7%). COPD has been 
estimated from 3.2% in France to 5.4% in the 
Netherlands. COPD is a major health problem across 
the world with its prevalence inversely proportionate 
to socioeconomic status. (4) 
Poorly ventilated cooking fires, often fueled by coal 
or biomass fuels such as wood and animal dung, lead 
to indoor air pollution and are one of the most 
common causes of COPD in developing countries. (5) 
Currently, the only inherited risk factor is alpha 1-
antitrypsin deficiency (AAT). (6) COPD is the 4th 
leading cause of death in the world, and there are 
further increases in the prevalence, morbidity and 
mortality of the disease. (7) 
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Significance: 
Chronic obstructive pulmonary disease (COPD) is a 
preventable and treatable disease state characterized 
by airflow limitation that is not completely 
reversible. Pulmonary rehabilitation has been well 
established and increasingly recommended in COPD 
and other chronic diseases management plans. 
Appropriate candidates are symptomatic patients 
with chronic lung disease who are aware of their 
disability and still motivated to actively participate in 
their own health care activity and program.  
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Diagnosis of COPD  primarily rely on a reduction of 
FEV1 and FVC ratio decrease <70% post 
bronchodilators therapy. (8) Assessment of COPD is 
based on the patient’s age, level of symptoms, 
exacerbation history, the severity of the spirometry 
report abnormality, and the related co-morbidities. 
Spirometry is now required to make a confident 
diagnosis of COPD. (2)  Management included 
smoking cessation, influenza and pneumococcal 
vaccines, workplace health strategies, pulmonary 
rehabilitation, bronchodilators, corticosteroids, long 
term oxygen, surgery and stem cell therapy. (9)  
Pulmonary rehabilitation is an evidence-based, 
multidisciplinary, and comprehensive intervention for 
patients with chronic respiratory diseases who are 
symptomatic and often have decreased daily life 
activities. Focused onto the individualized treatment of 
the patient, pulmonary rehabilitation is designed to 
reduce patient symptoms, optimize functional status, 
increase participation, and reduce health care 
utilization through stabilizing or reversing systemic 
manifestations of the disease. The aim of pulmonary 
rehabilitation is to break this vicious cycle and help 
the COPD patients to take part in daily activities. (10) 
Pulmonary rehabilitation has been well established and 
increasingly recommended in COPD and other chronic 
diseases management plans. Main elements included a 
multidisciplinary team, focus on the individual patient, 
and attention to emotional, psychological, social and 
physical aspects of health care. Appropriate candidates 
are symptomatic patients with chronic lung disease 
who are aware of their disability and still motivated to 
actively participate in their own health care activity 
and program. Pulmonary rehabilitation program has 
also been recommended and useful for patients with 
other types of chronic lung diseases. (11) 
Pulmonary rehabilitation may be beneficial for all 
patients in whom respiratory symptoms are associated 
with decreased/diminished functional capacity or 
reduced health related quality of life (HRQL). (12) It 
has been known to improve exercise capacity, dyspnea 
and health related quality of life in COPD following 
COPD. (13) Pulmonary rehabilitation induces 
important changes on depression and anxiety 
independent of changes in dyspnea and health-related 
quality-of-life. (14) 
Morbidity measures traditionally include physician 
visits, emergency department visits, and 
hospitalizations time duration. Although COPD 
databases for these outcome parameters are less 
readily available and usually less authentic than 
mortality databases, the limited data available indicate 
that morbidity due to COPD increases with age and is 
greater in men than in women. (15) 
Improved air quality can prevent COPD or slow down 
the worsening of existing disease. Annual influenza 
vaccinations in COPD reduce exacerbations, 
hospitalizations and death. (16) Keeping away people 
from starting smoking is a key aspect of preventing 
COPD as well as use of medications such as nicotine 
replacement therapy, bupropion (17). The rationale of 
this research was to see the effectiveness of pulmonary 
rehabilitation in stable COPD patients. The research was 
aimed to reduce disability and handicap in people with 
chronic lung disease and to improve their quality of life.  
Materials and Methods 
Study Design: It was a Randomized clinical trial. 
Setting: The data was collected from Gulab Devi 
Hospital Lahore 
Duration: The study was conducted in 4 months from 
November 2015 to February 2016  
Sample Size: We included 70 patients of COPD. 
Sample size was calculated based on COPD prevalence 
i.e., 11.8%. Samples were divided in two groups A and 
B. Group A comprised of patients with conventional 
treatment while Group B patients comprised of patients 
taking pulmonary rehabilitation in addition to 
conventional treatment. 
Sampling Technique: Convenient sampling 
Inclusion Criteria: COPD patients with mild to severe 
COPD, stable patients with age 40-65, FEV1 40-80%, 
FEV1/FVC >65%, FCV 35-70%, paO2 >55% were 
included in this study. 
Exclusion criteria: Exclusion criteria include 
significant orthopedic or neurologic problems that 
reduce mobility or cooperation with physical training. In 
addition, poorly controlled coexisting medical 
conditions, especially psychiatric or unstable cardiac 
disease, may limit participation, thereby making the 
patient an unsuitable candidate. Patients with very 
severe COPD and Cor-pulmonale were also excluded. 
Statistical Analysis: Both descriptive and inferential 
statistics were done in Statistical Package for Social 
Sciences (SPSS) version 16.00.  
Results 
Mean age of patients was 53.96 + 6.471 with maximum 
age of 66 and minimum age of 45 years. In our study 32 
(45.71%) patients were male; 3 (4.29%) patients were 
female in group A; 33(47.14%) patients were male and 2 
(2.86%) patients were female in group B as shown in 
Figure 1.  
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In our study, 32 (45.71%) were smoker in group A, and 
33 (47.14%) were smoker in group B. 3 (4.29%) were 
non-smoker in group A and 2(2.86%) were non-smoker 
in group B as shown in Figure 2. 
Table 1 showing chi-square value at baseline is 2.132 
and P-value 0.545. Chi-Square value after 10 days is 
1.701 and P-value is 0.129. Chi-square value after 20 
days in 0.058 and P-value is 0.810. 
This study also showed baseline CXR of group A had 17 
(24.29%) patients with hyperinflation, 8 (11.43%) hyper 
translucency, 6 (3.57%) patchy shadows, 4 (5.71%) 
other abnormalities. While baseline CXR of group B had 
20 (28.57%) hyperinflation, 10 (14.29%) hyper 
translucency, 3 (4.29%) patchy shadows, 2 (2.86%) 
other abnormality. After 10 days, CXR improvement of 
group A was 8 (11.43%) and group B CXR 
improvement was 13 (18.57%). After 20 days, group A 
improvement was 19 (27.14%) and improvement in 
group B CXR was 20 (28.57%). 
 
  
 
 
Table 2. Comparison of FEV1/FVC of group A (conventional treatment) 
and group B (conventional treatment + PR) 
 Severity  Group 
A 
Group 
B 
Chi-
square  
P-
value  
FEV1/FVC 
Baseline 
Mild  8 8 
 
 
 
0.076 
 
 
0.963 Moderate  15 
 
16 
Severe  
 
12 11 
 
 
FEV1/FVC 
After 10 days 
Mild  
 
7 10  
 
1.289 
 
 
0.525 Moderate  
 
15 16 
Severe 
 
13 9 
 
FEV1/FVC 
After 20 days 
 
Mild  
 
4 11  
 
4.933 
 
 
0.085 Moderate  
 
17 16 
Severe  
 
14 8 
Table 2 showing chi-square value at baseline is 0.076 
and P-value is 0.963. Chi-square value after 10 days is 
1.289 and P-value is 0.525. Chi-square value after 20 
days is 4.933 and P-value is 0.085. Baseline Group A 
FEV1/FVC was mild in 8 (11.43%), moderate 15 
(21.43%) and severe was 12 (17.14%), while group B 
FEV1/FVC was mild in 8 (11.43%), moderate 16 
(22.86%) and severe 11 (15.17%). After 10 days, Group 
A FEV1/FVC was mild in 7 (14.29%), moderate 15 
(2.43%) and severe was 13 (18.57%), while group B 
FEV1/FVC was mild in 10 (14.29%), moderate 16 
(22.86%) and severe 9 (12.86%). After 20 days, group A  
Table 1. Comparison of chest X-Ray of group A (conventional 
treatment) and group B (conventional treatment + PR) 
 Group 
A 
Group 
B 
Chi-
square  
P 
Value 
CXR 
baseline 
hyperinflation 17 20 
 
 
 
 
2.132 
 
 
 
0.545 
Hyper-
translucency 
8 
 
10 
Patchy Shadows 6 3 
Other 
abnormalities 
4 2 
CXR 
after 10 
days 
Improved 
 
8 13  
1.701 
 
0.129 
Not improved 
 
27 22 
CXR 
after 20 
days 
 
Improved 
  
19 20  
0.058 
 
0.810 
Not Improved  
 
16 15 
Figure 1. Descriptive Statistics of gender of group 
A (conventional treatment) and group B 
(conventional treatment + PR) 
Figure 2. Descriptive Statistics of smoking history of 
group A (conventional treatment) and group B 
(conventional treatment + PR 
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FEV1/FVC was mild 4 (5.71%), moderate 17 (24.29%) 
and severe was 14 (20%), while group B FEV1/FVC 
was mild in 11 (15.71%), moderate 16 (22.86%) and 
severe 8 (11.43%).  
Table 3 explained PEFR: chi-square value at baseline is 
1.465 and P-value is 0.690. Chi-square value after 10 
days is 5.921 and P-value is 0.116. Chi-square value 
after 20 days is 14.396 and P-value is 0.002. None of 
baseline Group A patients had normal PEFR while mild 
limitation was found in 17 (24.29%), moderate 
limitation 15 (21.43%), severe limitation was 3 (4.29%). 
Group B found normal PEFR in 1 (1.43%) patient, mild 
limitation 14 (20%), moderate limitation 16 (22.86%) 
and severe limitation in 4 (5.71%). None of group A 
Patients had normal PEFR after 10 days while mild 
limitation in 12 (17.14%), moderate limitation in 20 
(28.57%), severe limitation in 3 (4.29%). Group B had 
normal PEFR in 3 (4.29%) patients after 10 days, mild 
limitation 17 (24.29%), moderate limitation 14 (20%) 
and severe limitation was 1 (1.43%). Baseline Group A 
Patients didn’t have any patient with normal PEFR, mild 
limitation in 12 (17.14%) patients, moderate limitation 
in 18 (25.71%), severe limitation in 5 (7.14%) while 
group B had normal PEFR in 10 (14.29%), mild 
limitation in 13 (18.57%), moderate limitation in 11 
(15.71%) and severe limitation was in only 1 (1.43%). 
Chi-square value at baseline is 8.090 and P-value is 
0.044. Chi-square value after 10 days is 5.118 and P-
value is 0.163, Chi-square value after 20 days is 17.249 
and P-value is 0.001. (Table 4) Mild FEV1 limitation in 
1 baseline group A patient was reported,  moderate 
limitation was in 17 patients, severe limitation was in 15 
patients and  very severe limitation in 2 patients while 
FEV1 group B reported mild limitation in 8 patients, 
moderate limitation in 16 patients  and severe limitation 
in 11 patients. After 10 days, group A patients reported 
mild FEV1 in 2, moderate limitation in 20, severe 
limitation in 12 and very severe limitation in 1 while 
group B patients reported mild FEV1 in 7, moderate 
limitation in 21 and severe limitation in 7. After 20 days, 
group A patients reported FEV1 with mild limitation in 
1, moderate limitation was in 17, severe limitation was 
in 15 and very severe limitation in 2 while group B mild 
limitation in 14, moderate limitation in 15 and severe 
limitation was in 6. 
As described in table 5, chi-square value at baseline is 
2.819 and P-value is 0.420, chi-square value after 10 
days is 12.65 and P-value is 0.005 and chi-square value 
after 20 days is 16.389 and P-value is 0.00. Baseline 
group A had normal spO2 in 4 (5.71%), mild hypoxia 16 
(22.86%) moderate hypoxia was in 15 (21.43%) while 
group B had normal spO2 in 3 (4.29%), mild hypoxia in 
21 (30%), moderate hypoxia in 10 (14.29%) and severe 
hypoxia was 1 (0.43%). After 10 days group A had 
normal spO2 in 2 (2.86%), mild hypoxia in 17 (24.29%) 
moderate hypoxia in 14 (20%) and severe was in 2 
(2.86%) while group B had normal spO2 in 9 (12.86%), 
mild hypoxia in 22 (31.43%), moderate hypoxia in  4 
(5.71%) and severe hypoxia was not present. After 20 
days group A had normal spO2 in 2 (2.86%), mild 
hypoxia 18 (25.71%) moderate hypoxia was 15 
(21.43%), while group B had normal spO2 in 16 
Table 3. Comparison of PEFR of group A (conventional 
treatment) and group B (conventional treatment + PR) 
 Group 
A 
Group 
B 
Chi-
square   
P-value 
 
 
 
PEFR 
Baseline 
Normal 0 1 
 
 
 
 
1.465 
 
 
 
0.690 
Mild 
limitation  
17 
 
14 
Moderate 
limitation 
15 16 
Severe 
limitation 
3 4 
 
 
 
PEFR 
after 10 
days 
Normal  
 
0 3  
 
 
5.921 
 
 
 
0.116 
Mild 
limitation  
12 17 
Moderate 
limitation 
20 14 
Severe 
limitation  
3 1 
 
 
 
PEFR 
after 20 
days 
 
Normal   0 10  
 
 
14.396 
 
 
 
0.002 
Mild 
limitation 
12 13 
Moderate 
limitation 
18 11 
Severe 
limitation 
5 1 
Table 4. Comparison of FEV1 of group A (conventional treatment) and 
group B (conventional treatment + PR) 
 Severity  Group 
A 
Group 
B 
Chi-
square   
P-
value 
FEV1 
baseline 
Mild  1 
 
8  
 
 
8.090 
 
 
 
0.044 
Moderate  17 16 
Severe   15 11 
Very severe   2 0 
FEV1 
after  
10 days 
Mild   
 
2 7  
 
 
5.118 
 
 
 
0.163 
Moderate  20 21 
Severe  
  
12 7 
Very severe   1 0 
FEV1 
after 
 20 days 
Mild  
  
1 14  
 
 
17.249 
 
 
 
0.001 
Moderate   17 15 
Severe   15 6 
Very severe   2 0 
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(22.86%), mild hypoxia in 14 (20%), moderate hypoxia 
in 5 (7.14%). 
Table 5. Comparison of SpO2 of group A (conventional 
treatment) and group B (conventional treatment + PR) 
 Group 
A 
Group 
B 
Chi-
square  
P-
value 
 
 
 
spO2 
baseline 
Normal 4 3 
 
 
 
 
2.819 
 
 
 
0.420 
Mild 
hypoxia  
16 
 
21 
Moderate 
Hypoxia  
15 10 
Severe 
Hypoxia 
0 1 
 
 
 
SpO2 
after 10 
days 
Normal  
 
2 9  
 
 
12.65 
 
 
 
0.005 
Mild 
hypoxia  
 
17 22 
Moderate 
hypoxia  
14 4 
Severe 
hypoxia  
2 0 
 
 
 
SpO2 
after 20 
days 
 
Normal   2 16  
 
 
16.389 
 
 
 
.000 
Mild 
hypoxia   
18 14 
Moderate 
Hypoxia 
15 5 
Severe 
hypoxia  
0 0 
Chi-square value at baseline is 4.597 and P-value is 
0.467, chi-square value after 10 days is 20.897 and P-
value is 0.002, chi-square value after 20 days is 20.010 
and P-value is 0.003 as showed in Table 6. Baseline 
BORG dyspnea scale of group A had very slight 0%, 
slight 2 (2.86%), moderate SOB 4 (5.71%), somewhat 
severe 8 (11.43%), severe 11 (15.71%), very severe 2 
(2.86%) while group B had slight 1 (1.43%), moderate 
SOB 9 (12.86%), somewhat severe SOB 11 (15.71%), 
severe 9 (12.86), and severe 1 (1.43%). After 10 days 
BORG dyspnea scale of Group A had very slight 0%, 
slight 0%, moderate SOB 6 (8.571%), somewhat severe 
6 (3.57%), severe 13 (18.57%) and very severe 1 
(1.43%) while group B had slight 5 (7.14%), moderate 
SOB 11 (15.71%), somewhat severe SOB 11 (15.71%), 
severe 5 (7.41%) and severe 0. After 20 days BORG 
dyspnea scale of group A had very slight 0%, slight 0%, 
moderate SOB 6 (8.57%), somewhat severe 8 (11.43%), 
severe 13 (18.57%), very severe 1 (1.43%) while group 
B had slight 6 (8.57%), moderate SOB 13 (18.57%), 
somewhat severe SOB 13 (18.57%), severe 2 (2.86%), 
and severe 0.  
Group A 6 minutes-walk test baseline t-value is -0.595 
and P-value is 0.554 with mean 53.63±7.276. Group B 6 
minutes-walk baseline t-value is -0.595 and P-value is 
0.554 with mean 54.8571±9.81938 described in table 7. 
Group A 6 minutes-walk after 10 days t-value is -0.636 
and P-value is 0.509, and mean was 54.0571±8.45383. 
Group B 6 minutes-walk after 10 days t-value is -0.636 
and P-value is 0.509 and mean is 55.5143±9.87085. 
Group A 6 minutes-walk after 20 days t-value is -2.709 
and P-value 0.009 is with mean was 51.3714±63674. 
Group B 6 minutes-walk after 20 days t-value is -2.709 
and P-value is 0.009 with mean was 57.4857±10.18468. 
Table 6. Comparison of BORG dyspnea scale of group A 
(conventional treatment) and group B (conventional treatment + 
PR) 
 Severity  Group 
A 
Group 
B 
Chi-
square   
P-
value 
 
Borg 
Dyspnea 
scale 
baseline  
Very 
slight 
0 0  
 
 
4.597 
 
 
 
0.467 
Slight  2 1 
Moderate  4 9 
Somewhat 
severe 
8 11 
Severe  19 13 
V severe  2 1 
 
Borg 
Dyspnea 
scale 
after 10 
days  
Very 
slight 
0 2  
 
 
20.897 
 
 
 
0.002 
Slight  0 5 
Moderate  6 11 
Somewhat 
severe 
6 11 
Severe  22 6 
V severe  1 0 
 
Borg 
Dyspnea 
scale 
after 20 
days   
Very 
slight 
0 2  
 
 
20.010 
 
 
 
0.003 
Slight  0 6 
Moderate  6 13 
Somewhat 
severe 
7 8 
Severe  21 6 
V severe  1 0 
Discussion  
The results of the study suggested small but statistically 
and clinically significant improvements of health-related 
quality of life in patients with COPD and immediately 
after participation. Mainly improvement occurs in Peak 
expiratory flow rate, BORG dyspnea scale, 6 mint walk 
test distance (meters) and Oxygen saturation after 
rehabilitation. Walking distance also improved in 
6MWT, but the effect was too small to be considered 
clinically relevant. Clinically there is a little effect on 
CXR pattern, FEV1 and FEV1/FVC after pulmonary 
rehabilitation. But overall quality of life improved after 
pulmonary rehabilitation. 
Group A 6 minutes-walk test baseline t-value is -0.595 
and P-value is 0.554 with mean 53.63±7.276. Group B 6 
minutes-walk baseline t-value is -0.595 and P-value is 
0.554 with mean 54.8571±9.81938. Group A 6 minutes- 
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walk after 20 days t-value is -2.709 and P-value 0.009 is 
with mean was 51.3714±63674. Group B 6 minutes-
walk after 20 days t-value is -2.709 and P-value is 0.009 
with mean was 57.4857±10.18468. So, there is increase 
in 6MWD after PR as compared to group A. As 
compared to other research We also found a statistically 
significant improvement of 25.71 m (95% CI: [15.76-
35.65]) in the 6-minute walk test with PR (18). 
In our study P-value for FEV1/FVC at baseline is 0.96, 
and P-value after 20 days is 0.085 so there is little 
improvement in FEV1/FVC and FEV1 after PR. As 
compared to other research there were also no 
significant changes in pulmonary function test results 
(FEV1, FVC, and FEV1/FVC), minute ventilation, 
breathing frequency, or tidal volume at rest or exercise 
after pulmonary rehabilitation. After PR there was 
significant improvement in maximal oxygen uptake and 
work rate improvements of exercise capacity, respiratory 
muscle strength, maximum oxygen pulse, and 
exertional dyspnea scores (all P < .05) (19). 
In our study BORG dyspnea scale was also improved 
significantly after pulmonary rehabilitation. at baseline 
P-value for BORG dyspnea scale is 0.467,  but P-value 
is 0.003 after 20 days of PR. Baseline BORG dyspnea 
scale of group B had slight1 (1.43%), moderate SOB 
9(12.86%), somewhat severe SOB 11(15.71%), severe 
9(12.86), and severe 1(1.43%)  After 20 days BORG 
dyspnea scale of group B had slight 6(8.57%), moderate 
SOB 13(18.57%), somewhat severe SOB 13(18.57%), 
severe 2(2.86%), and severe (0%)  As compared to other 
study the dyspnea scores evaluated with MRC showed 
significant improvements (P < 0.001). HRQoL and 
exercise capacity were significantly improved for the 
two groups (P < 0.001) (20) 
As compared to another 
research Exercise 
capacity, muscle force, 
quality of life, and 
functional status 
improved significantly 
after 3 months of 
pulmonary 
rehabilitation (all p < 
0.05), Movement 
intensity during walking 
improved significantly 
after 3 months (p = 
0.046) with further 
improvements after 6 
months (p = 0.0002). 
Walking time in daily 
life did not improve 
significantly at 3 
months (mean improvement, 7 ± 35%; p = 0.21), but 
only after 6 months (mean improvement, 20 ± 36%; p = 
0.008). No significant changes occurred in other 
activities or in the pattern of the time spent walking in 
daily life. Changes in dyspnea after the program were 
significantly related to changes in walking time in daily 
life (r = 0.43; p = 0.02) (21). 
As compared to another research Overall, patient health-
related quality of life (HRQoL) and Exercise capacity 
assessed by a 6-min walking distance test (6MWD) was 
similarly significantly improved. However, there was 
some fall-off in terms of the distance walked 12 months 
after pulmonary rehabilitation. The improvements in 
exercise capacity, dyspnoea, and HRQoL did not differ 
between the two groups, with the exception that the 
6MWD (P < 0.01) at 3 months post-pulmonary 
rehabilitation were significantly higher in the old-elderly 
group (22) while in our study P value after PR for 
6MWD is 0.009 and for dyspnea scale P value is 0.003. 
Education of workers about the risks, smoking cessation, 
 checking  workers for early signs of COPD, use 
of respirators, and dust control (23). A number of 
measures have been taken to reduce the incidence that 
workers in at-risk industries such as coal mining, 
construction and stonemasonry will develop COPD.    
Conclusions  
Pulmonary rehabilitation proposed where patients who 
feel a loss of control as their disease advances may find 
that pulmonary rehabilitation offers them the 
opportunity to regain control. These results showed 
that patients with COPD had benefited from a 
comprehensive PR program in an out-patient setting 
regardless of disease severity. Even patients with earlier 
Table 7. Comparison of 6 minutes walk test of group A (conventional treatment) and group B 
(conventional treatment + PR) 
  groups 
of 
patients Mean 
Std. 
Deviation 
 
T 
 
P-value 
 6 mint walk test 
baseline (meters) 
 group A 
 
53.6286 7.27642 
- 0.595 0.554 
 group B 
 
54.8571 9.81938 
- 0.595 0.554 
 6 mint walk test after 
10 days (meters) 
 group A 
 
54.0571 8.45383 
- 0.636 0.509 
 group B 
 
55.5143 9.87085 
- 0.636 0.509 
6 mint walk test after 
20 
 days (meters) 
 group A 
 
51.3714 8.63674 
- 2.709 0.009 
 group B 
 
57.4857 10.18468 
- 2.709 0.009 
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Patients 
stage of disease should be referred and encouraged to 
participate in a PR program Exercise training can result 
in significant improvement in health-related quality of 
life, exercise capacity, respiratory muscle strength, and 
exertional dyspnea in subjects with COPD and normal 
exercise capacity. 
Conflict of Interest: This study has no conflict of interest to 
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